EFTA00598622

Morgan Stanley MORGAN STANLEY RESEARCH NORTH AMERICA 7.1;r4.-.713er Jey e C.; _LC. Matthew Harrison • David Friedman. M. J , 21 2: I - Stock Rating Gilead Sciences Inc. Equal-weight Industry View HCV Still Near and LT Focus In-Une Key Ratios and Statistics Upside Sovaldi (4611M vs cons) drove a $0.57 Reuters: GILD.O Bloomberg: GILD US EPS beat: Sovaldi (4611M), Truvada (+$18M), Viread Biotechnology / United Stales of America (+$24M) and Complera (+$22M) drove the $685M rev Shr price. close (Jul 23. 2014) $90.34 beat vs cons. Better gross margins (89% vs MSe 86%) Mkt cap. curt (mm) $152.143 and a lower tax rate (14.6% with a 1 qtr 3.6% catch-up) 62-Week Range $90.74-55.96 represented the majority of the delta between our $2.14 and Gilead's reported EPS of $2.36. Mgt. also gavels' Fiscal Year ending 12/3 12/14e 12/15e 12/16e time guidance incorporating Sovaldi with revs of $21- ModelWare EPS (5) 2.05 8.16 9.19 10.17 23B (prior $11.3-11.56). This suggests 2H Sovaldi revs Prior ModelWare EPS ($) 7.58 8.42 9.64 of -'$3.945-5.745B, below the 1H total of $5.7558. Mgt. PIE 36.7 11.1 9.8 8.9 cited warehousing and inventory destocking ahead of Consensus EPS ($)§ 1.98 6.73 8.22 9.35 the all-oral launch as potential contributing factors. Div yld (%) 0.0 - 0.5 1.2 Unless othenvaa noted. all metrics ate based on Morgan Stanley ModetWare Sovaldi still the centerpiece: Near and long-term framework (please see explanabon later in Ills note) Sovaldi sales continue to dominate the debate. On the § a Consensus data is provided by Thomson Reuters Estrne: a a Morgan Stanley Research estimates near-term, guidance seems to imply a seq. deceleration for 3O followed by an uptick in 4O after the all-oral launch, inline with our model. Hwr, with the implied 2H run-rate below 1H reported sales, it appears a modest disappointment vs high expectations. Nonetheless, sig. investor expectations for an early all-oral approval ahead of the 10/10 PDUFA (and the assoc sales bolus) is likely to offset any guidance concerns. While we agree early approval could represent 2014 upside, it could conversely make the 2015 comp that much harder. On the LT, our view remains that there are risks to sustainability of the HCV franchise. Separately, the early approval of idelalisib (CLL & iNHL) was a nice positive offset by the boxed warning and REMS. We still see it as a 10-15% mkt share drug with $1B+ pot. Capital allocation continues to represent the other LT driver, but mgt. Isn't pointing to a deal: While mgt. repurchased 15.2M shares in the qtr ($1.28) and said it will finish another $1.78 in buybacks by Sept., a near-term deal to ease LT Sovaldi tail concerns didn't appear immine a see continued investor focus on dividends and as the cash from Sovaldi builds. We expect a muted stock reaction even as Sovaldi delivered given high expectations: We believe cons Morgan Stanley does and seeks to do business with expectations of a Sovaldi beat have been a major companies covered in Morgan Stanley Research. As driver of GILD over the last few weeks, thus the beat a result. investors should be aware that the firm may have a conflict of interest that could affect the was widely expected. With guidance not suggesting sig. objectivity of Morgan Stanley Research. Investors upside to cons, we expect GILD to not move much should consider Morgan Stanley Research as only a tomorrow. Our 2014E/2015E EPS ests move modestly single factor in making their investment decision. higher to $8.17/$9.19 ($7.58/$8.43 prior) on tax-rate, For analyst certification and other important gross margin and share count changes to our model. disclosures. refer to the Disclosure Section, lo cated at the end of this report. EFTA00598622 Morgan Stanley MORGAN STANLEY RESEARCH July 23. 2014 Gilead Sciences Inc. Risk-Reward Snapshot: Gilead (GILD, EW, PT $81) Sovaldi peak and duration, HIV patent expirations drive Risk-Reward Investment Thesis Exhrlal 1 S 160 We are EW Gilead as we believe some of the risks around HCV have been 140 overlooked suggesting risk to out-year estimates. This is balanced by the 120 potential for a solid hemionc franchise in 100 idelalisib and time to switch HIV patients away from therapies that go generic. 60 • HCV (Sovaldi): HCV demand is off to a 60 strong start with sales likely of at least $10B in the first year. That said, we 40 don't have confidence that peak 20 revenues will continue after all the patients in care are treated (-2017E). 0 We highlight risks on multiple fronts JS-12 Jan-13 Jul-13 Jan-14 Jul 14 Jan-15 Jul-1S including pricing. competition and high • FiriooTanpi(Jul-15) 1.1abmiceiSiod.Poitomionoo • CocroniSiockPeco consensus expectations. Source: Morgan Slarty Research estimates. Thomson Reuleis Price We derive our PT from a discounted cash flow analysis that uses a WACC of 10•% and • HIV: Gilead has done a good job of Target a 2% terminal growth rate. The main drivers are the HIV franchise and Sovaldi. switching naïve patients to the new $81 STRs (Stribild and Complera), but The number of treated HCV patients do not decline post 2017E TruvadaiAtripla still hold -60% of the Bull DCF Case and competition is less robust; Gilead transitions more than market right now. which means a half of HIV sales to new regimens We assume: significant number still need to be $145 1) -35B in 2020E antiviral sales. of which 6168 is from HCV. switched. This is a potential source of 2) The number of naive US HCV patients treated is stable at -2001vyr. LT risk. However. there is still time and 3) HCV pricing is not impacted by competition, and we've yet to get all the TAF data. 4) CompleraiEvipleraiStribild/TAF take -60% patient share of HIV Base DCF US treated HCV patients decline modestly post 2017E, around • Oncology (Idelalisib): We believe Case half of HIV sales are transltioned to new regimens. We assume: idelalisib can be a $1-2B US asset. 1) -208 in 2020E antiviral sales. of which -$62 is from HCV. $81 2) The number of naive US HCV patients treated declines to That said. duration of therapy is -115Wyr. currently unclear (the major driver of 3) HCV pricing is modestly impacted by competition (-15%). and sales) given the liver function issues. If 4) ComplerarEvipleraiStribild/TAF take -35% patient share of HIV LFTs cause short duration. there could Bear DCF Rapid peak and then erosion of the HCV market, HIV cliffs: be downside to sales. However. we Case 1) -9B in 2020E antiviral sales. of which -$500M is from HCV. note expectations are modest. 2) The number of naive US HCV patients treated declines to $34 baseline. 3) HCV pricing/share is aggressively impacted by competitors (- Risks to our price target 70%). 1) A longer peak to HCV sales. 2) A 4) ComplerarEviplera/Stribild/TAF take -20% patient share of HIV higher peak of HCV sales followed by a rapid decline. 3) Unexpected toxicity or competition in HCV, 4) Unexpected toxicity in idelalisib, 5) Early pipeline success for simtuzumab 2 EFTA00598623 Morgan Stanley MORGAN STANLEY RESEARCH July 23. 2014 Gilead Sciences inc. Exhibit 2 Gilead 2014 Variance MSe 2O14E 2O14A Consensus MSe %YiY Actual % Y/Y Difference 2O14E* Difference Product Sales (WW): Atripla $923 -2% $871 -7% -6% $875 ($4) 0% Tmvada $807 0% $807 0% 0% $789 $18 2% Viread $269 8% $261 4% -3% $237 $24 10% CompleraiEviplera $265 40% $299 59% 13% $277 $22 8% Stribild $248 150% $270 171% 9% $262 $7 3% Sovaldi 53.625 NM $3,481 NM -4% $2.870 $611 21% Other $30 NM $24 •13% •19% Total Antiviral Products $6.197 168% $6,012 160% .3% Letairis $156 22% $145 13% -7% $134 $11 8% Ranexa $129 21% $122 14% •5% $119 $3 2% AmBisome $89 18% $95 26% 7% $87 $7 8% Cayman $40 18% $39 16% -2% Other $1 •13% $0 NM MN Total Product Sales $6.612 149% $6.413 141% •3% $340 56.073 1784% Royalty. Contract. Other Revs $93 •16% $122 11% 31% Total Revenues $6.705 142% $6,535 136% -3% $5.850 $685 12% COGS $927 40% $723 9% -22% Gross Profil $5.778 174% $5,812 176% 1% M $575 18% $542 11% -6% SG&A $535 42% $569 51% 6% Operating Income $4,668 276% $4,701 278% 1% Interest Expense. Nel ($76) NM ($102) NM 34% Other Income (Expense). Nel ($20) NM ($4) NM -82% Pretax Income $4,572 293% $4,595 295% 1% Taxes $963 192% $671 104% -30% Tax tale 2f% •26% 15% -48% -31% Net loss from noncontroiling interest ($5) NM ($5) NM 6% Net Income (Non-GAAP) $3,613 330% $3,930 368% 9% Non-GAAP EPS (excl. options) $2.14 331% $2.36 376% 11% $1.79 $0.57 32% GAAP EPS $1.96 331% 52.20 382% 12% Diluted Shares Outstanding 1678 1663 NM Gross Margin 86% 13% 89% 17% 3% 85% M (% of Sales) 9% •51% 8% -53% -3% SG&A (% of Sales) 8% -41% 9% -36% 9% Operating Margin 70% 55% 72% 60% 3% Seine: Company Dela. Morgan Santry Research 3 EFTA00598624 Morgan Stanley MORGAN STANLEY RESEARCH July 23. 2014 Gilead Sciences Inc. Exhitin 3 Gilead Income Statement 2009 2010 2011 2012 2013 2014E 2015E 2016E 2017E 2018E 2019E 2020E GIN% Scene $1410inen1 10144 20144 3014E 4014E Produci5.0% 6.469 7.350 8002 9.3% 10.804 4171 6.413 5.796 7.672 24.813 27.797 29.280 26.763 25.286 22933 22660 Rey=0•1441(1011* MM.* 542 559 283 301 316 128 122 71 43 365 377 390 403 418 433 448 Toll R.ynae 7.011 7949 8.385 9.7% 11902 4.999 6.636 6867 7.716 25.171 26.174 29.670 27.166 25.703 23.364 23.100 5.530 6257 22.628 0008 1.533 1.793 2.046 2.401 2.708 611 723 964 1.233 3.532 4.679 4.909 4.647 4.544 4.434 4.491 Or048 P7041 6481 1157 1339 7.302 8.493 4.388 5.812 4.903 6.482 21.646 23.495 24,761 22519 21.159 18932 18.618 631 839 1.119 1.4% 1.948 558 542 600 660 350 2.515 2.691 2325 2.896 2.968 3.042 Go, 061044101 32 3-2.4B $06A 820 913 1.091 1.226 1.557 500 569 2.703 2.973 3.121 3.090 3.059 3.029 Operailna Income 3.430 4.405 4.126 41490 4.988 3930 4.701 663 5.161 15.946 18.278 19.098 16972 16.173 12.961 12447 Mem, 4/wee -70 -109 -182 .307 -76 '102 -102 .82 363 -400 383 364 .341 -343 -332 Cesar income (emonso. nal 42 60 67 .37 -20 -4 67 30 123 239 325 371 376 356 Pian none 1803 4357 4011 4.189 4.673 3934 4.595 3.587 5.136 16.614 16.000 19.954 16934 15.202 12.939 12971 Tates 950 1.154 987 1.123 1.240 751 671 636 663 3.020 2.732 2.308 1.848 1.851 1.705 1.782 Tar Rate 25% 26% 15% 17% 17% 22% 15% It% 77% 032% 15% /2% //IS /2% 13% 14% Net Moose 0.644,10) 2443 3.203 3.024 3036 3.433 2.483 15268 18.645 14486 13.350 11233 10.789 Na loss Inn noncortrohna emoted. '10 '12 'IS 44 '18 5 5 5 II 'II 'II 0 0 0 0 NM Income 10 Gilead 61440-08.481 2853 9,214 AO* 3,004 3.451 Mae 3230 2.957 4.213$ 13.611 11286 16863 14.686 13.350 11233 10.789 7k4semp tPs5na 0646580 $584 $183 096 82.0$ $1.48 1136 11.78 1296 $8.17 $9.19 $10.18 1932 96.96 18.05 1840 ipallesus 1.62 7.94 6.73 8.23 935 M75 Nen gaap EPS(al. omons) $1.46 $1.76 EIS $1.73 61.91 $1.44 $232 $1.74 $253 5901 5333 59,94 6905 $166 $788 $787 GOAP EP5 Owl comes/ $1.41 $1.66 $1.77 $1.64 41.32 $1.32 $220 $1.60 $249 $7.97 $5.98 $9.94 $805 $4.64 $788 $7.86 Eitiee %OM • GAAP 1409 1.712 1.615 1.515 1.529 1.537 1.533 1.532 1.531 1.526 1523 1.499 1.443 1.366 1278 1.190 MAW Shares. CIAAP 1ass 1.747 1.550 1.583 1.686 1.680 1.664 1.663 1.662 1667 1.664 1.638 1576 1.491 1.397 1,300 DAM Shares- eon4144P 1.818 1.743 1.576 1.590 1.685 1.679 1.663 1.662 1.661 1.626 1.663 1.637 1.576 1.490 1.396 1.300 COGS (poaduci revensa) 24% 24% 25% 28% 25% 13% 11% 24% 26% 25% 25% 25% 25% 25% 24% 26% Goss Mamie (Mel awenue) 78% 77% 78% 75% 76% 88% 89% 84% 84% 86% 83% 83% 83% 82% 81% 81% Co. Oulciance 85-88% A (es 3%43 44881 12% 11% 19% 13% 14% 10% 9% 14% 14% 14% 14% 14% 14% 14% 14% S (es a %Oita%) Operang lMrgm 12% 55% 11% 55% 13% 49% 15% 47% 17% 45% 11% 67% 8% 72% 18% 63% 15 16% 67% 17% 67% 17% 65% 17% 64% 17% 61% 17% 59% 17% 55% 17% 54% 58170.0 slaty 58% 59% 53% 50% 48% 69% 73% 65% 68% 69% a% 66% 63% 61% 91% 57% Nel /Malin 41% 40% 36% 32% 31% 50% 60% 50% 55% 54% 54% 66% 54% 52% 48% 47% "'" ."7-6(11/1• Nei 120(11.1617611619 27% 14% 10% 16% 15% 104% 141% 114% 152% 133% 12% 5% -9% 4% 4% Total revenue 31% 13% 5% 16% 15% 97% 136% 111% 147% 125% 12% 5% 41% 4% .1% COGS 37% IT% 14% 17% 13% 0% 9% 46% 59% 30% 32% 5% 4% 1% - 3064 27% 14% 1% 11% 33% 34% 12% 30% 21% 50% 11% 23% 27% 42% 21% 7% 7% 5% 2% -1% 2% 2% -1% 20% V% 51% 62% 51% 15% 10% 5% -1% 00On% AS& OMIT/ 3% 1% -11% -4% 4% 50% 60% 39% 53% 51% -4% -1% 4% -3% 4% -2% ESIMAmarqn 3% 2% .10% 4% -5% 43% 53% 34% 47% 45% -4% •1% .5% -3% .5% 3% Seine: Germany Dela Morgan Stanley Research EFTA00598625 Morgan Stanley M0RGAN STANLEY RESEARCH July 23. 2014 Gilead Sciences Inc. EPhitA 4 Gilead Product Revenues (1 of 2) Product Revenue 20094 2010A 2011A 2012A 20134 2014E 2015E 2016E 2017E 2018E 2018E 2020E 1014 2014 3014E 4014E woe 2,382 2927 3,225 3.574 3,648 780 871 917 1.009 3,577 3,572 3,559 3405 3,331 2.741 2,534 US (2021 Expiator') 1.646 1.909 2.022 2253 2.356 490 sea 610 678 2.356 2.447 2.507 2505 2.503 2.500 2.497 EU (2018 Expkarn:nl 678 910 1.043 1.103 1,062 237 234 237 270 978 869 782 717 573 177 20 ROW 59 106 160 219 231 53 56 71 61 243 256 269 283 255 64 16 Runde 2,490 21650 2,875 3.181 3,136 760 807 803 799 3,169 3,140 3,125 3.124 2,779 2.139 1,892 US (2021 Expired:ell 1.178 1.309 1.385 1813 1.570 368 400 430 448 1.645 1.679 1.711 1.742 1.771 1.797 1.822 EU (2018 ExpOixonl 1.170 1.171 1.257 1316 1296 323 338 300 278 1.240 1.163 1,101 1.054 844 259 ea ROW 142 170 232 253 270 69 69 73 73 284 296 313 326 164 82 41 EtNi Plowed WM 732 849 969 211 261 249 294 1.014 1.064 1,113 1.166 822 241 29 US (2018 Explremn. Teva cetWemen0 290 320 388 428 81 117 115 121 433 432 430 425 304 81 8 EU (2018 Expiration) 273 293 336 354 84 88 93 117 382 408 430 454 318 100 15 ROW 105 119 125 177 46 57 41 56 199 224 253 286 200 60 6 oodll CompleradEvIpbra 342 809 261 299 310 362 1.212 1.689 2.292 2.604 2.101 20418 2.943 US (2023 Explre0:01 280 503 130 154 195 237 717 1.043 1.453 1.566 1.673 1.788 1.910 EU (2022 Experaecni 53 268 109 132 MO 97 438 569 749 834 914 910 912 ROW 9 39 it 13 15 19 58 75 91 104 115 120 120 Stribid 68 639 216 270 289 316 1.080 1.911 2.787 3.346 3863 4.132 4,418 US (2029 Expealen) 58 510 187 229 223 206 646 1.330 1.820 2.111 2346 2596 2.862 EU (2027 Expiraton) 24 24 31 51 102 208 534 698 1.154 1.416 1,430 1.448 ROW 0 5 5 9 15 7 36 53 69 80 92 105 111 TAF 474 998 1,372 1,800 1,995 US (20222029 Expiration) 446 834 1.072 1.326 1.407 EU (202112027 Expiration) 23 129 248 404 510 ROW 5 35 53 68 78 SovNdl 139 2.274 3,481 2,765 4,374 12,894 14.073 13,649 10.045 8,471 7219 7,016 US (2029 Expiation. 2030 for FCC) 136 2 098 3.032 2.100 3.590 10.619 9,212 7.394 5,247 4.645 4.041 3.933 EU (2028 Expiration. 2029 for FCC) 3 164 401 600 680 1.845 3.559 4.240 2.750 2.078 1519 1.302 ROW 0 3 49 65 104 231 1.302 2.015 2.047 1.750 1.659 1.782 Other AMIvIrgl 300 228 173 138 109 18 24 25 55 123 152 164 193 237 266 301 CoblcIsnoTybora (2027 Expiration) 10 15 25 100 125 150 165 180 195 TOW ArelVela Product* 5,839 6537 7,050 6.142 9,340 4,506 6012 5.369 7214 23,104 25,706 26,813 24.032 22,359 19,736 19,328 Soiree. Company Da Morgan Stanley Research EFTA00598626 Morgan Stanley MORGAN STANLEY RESEARCH July 23. 2014 Gilead Sciences Inc. Exhibit 5 Gilead Product Revenues (2 of 2) Product Revenue 2009A 2010A 2011A 2012A 2013A 2014E 2015E 2016E 2017E 2018E 2019E 2020E 1014 2014 3014E 4014E Letalas (US Only . Patent ExpluMon 2018) 184 240 293 410 520 123 145 156 156 624 718 789 852 639 320 64 Raneaa (US Only. Patent Expiratean 2019) 131 240 320 373 449 ❑2 122 129 129 516 593 682 771 856 933 700 AmEusome (US Paten] 2016: EU 2008) 299 306 330 347 352 92 95 89 89 314 359 305 153 IS 2 0 Other Products 17 67 109 127 143 36 39 53 84 210 422 690 955 1.416 1.943 2.569 Cayston (US 4, EU Patents 2021) 48 91 107 139 36 39 42 44 161 185 207 228 246 261 271 Other 17 19 18 20 4 0 0 I i 4 4 4 4 4 4 4 Idelalisib (2025 Esplreti0n) 10 39 49 233 479 723 1.166 1,678 2,294 Total Product Sales 6,469 7.390 8,102 9.398 10,804 4,871 6,413 5,796 7,672 24,813 27,797 29.280 26,763 25,286 22,933 22,660 Royatly.contract and other revenue 542 559 283 304 398 128 122 71 43 366 377 390 403 418 433 448 Royalty Revenue 492 546 269 291 384 120 118 68 40 351 363 376 389 404 419 434 Tamill3 RayateS 393 387 76 44 13$ 52 58 5 -25 90 90 90 90 90 90 90 Other PoyaTher, 99 159 193 247 249 72 60 63 65 261 273 286 300 314 329 345 Contract and other revenue 50 14 14 14 14 4 4 3 3 14 14 14 14 14 14 14 Total Rev nu 7,011 7,949 8,385 9,703 11,203 4,999 6,535 5,867 7.716 25,178 28,174 29.670 27,166 25.703 23.366 23,109 Smote: Company Data. 1.5angan Stanley Research EFTA00598627 Morgan Stanley MORGAN STANLEY RESEARCH July 23. 2014 Gilead Sciences Inc. Exhite 6 Gilead Balance Sheet 2009 2010 2011 2012 2013 2014E 2015E 2016E 2017E 2018E 2019E 2020E Current assets Cash and Equivalents 1.273 908 9.884 1.804 2.113 10.875 21.989 30255 34.444 34.626 32.346 27.517 Marketable Securities 384 1.191 16 59 19 530 989 1.403 1,776 2.111 2.413 2.684 Trade Receivables. nel 1.390 1.622 1,951 1.751 2.100 4,721 5.282 5.563 5,094 4.819 4.381 4.333 Inventories 1.052 1.204 1,390 1.745 2.056 2,681 3.552 3.726 3,528 3.449 3.366 3.409 Deferred Taxes. Net 295 279 208 263 331 331 331 331 331 331 331 331 Prepaid Expenses & Taxes 352 388 342 535 564 1,385 1.409 1.483 1,358 1.285 1,168 1.155 Other Current Assets 67 116 127 0 92 378 394 415 380 386 350 347 Total current assets 4,813 5.708 13,919 6,156 7274 20.899 33247 43.177 46.910 47.006 44.354 39.775 Property. Plant & Equipment. Net 700 701 774 1,100 1.166 1.521 1.960 2.455 2.904 3224 3,680 4.029 Non-Current Portion of Prepaid Royalties 226 204 175 176 199 225 254 287 325 367 415 470 Non-Current Deferred Tax Asset 101 153 144 131 155 155 155 155 155 155 155 155 Intangible Assets. net 1,062 893 2,067 11,736 11.900 11.658 11.416 11.174 10.932 10,690 10,448 10206 Long Term Marketable Securities 2,248 3.219 64 720 439 439 439 439 439 439 439 439 Goodwill 463 533 0 1.061 1.169 1.169 1,169 1.169 1.169 1.169 1.169 1.169 Other Assets 86 181 161 159 195 413 435 428 392 371 374 370 Total assets 9.699 11,593 17.303 21,240 22.497 36.479 49.774 59.284 63.225 63,521 61.034 56.612 Current liabilities Accounts Payable 811 803 1.206 1,327 1.256 1,638 2,170 2,276 2,155 2,107 2,056 2,082 Accrued Expensestomp & Employee Ben. 132 148 173 237 244 547 613 645 591 559 508 502 Accrued Liabilities 800 765 1,059 1,433 2.018 1,860 1,826 1.982 2,081 2.095 2,110 2,125 Deferred Revenue 123 103 75 103 111 111 111 111 111 111 111 111 Curren1 Portion of Long Term Debt 6 646 2 1.169 2.697 0 1,167 0 0 0 0 0 Total current liabilities 1,872 2.465 2,515 4,270 6.325 4.176 5.885 5.014 4.938 4.872 4.784 4.920 Deferred Tax Liabilities 87 107 136 116 162 162 162 162 162 162 162 162 Long-Term Debt 1,155 2239 7.606 7.055 3.939 9,821 7.932 7.932 7.232 7.232 7.232 6,733 Long-Term Deferred Revenue 43 33 32 21 22 22 22 22 22 22 22 22 Other long.term obligations 36 27 148 228 304 904 904 904 904 904 904 904 Total liabilities 3,193 5.471 10.436 11,689 10.752 15.085 14,905 14.034 13.258 13.192 13,105 12.642 &enmity Interest 138 258 128 241 375 358 340 323 323 323 323 323 Preferred Stock 0 0 0 0 0 0 0 0 0 0 0 0 Common Stock 1 1 1 1 2 2 2 2 2 2 2 2 Additional paid-in capital 4.377 4.648 4,903 5,650 5.387 4,870 4.172 -82 -7.488 -17.435 -28,411 -40.551 (Accumulated Deficit) Retained Earnings 1.995 1.184 1.777 3.705 6.105 16.289 30.479 45.132 57.255 67.564 76.141 84,322 Accumulated Other Comprehensive Income -6 31 58 -46 .124 .124 -124 -124 -124 -124 .124 -124 Total stockholders' equity 6,367 5.864 6.739 9,310 11.369 21.036 34,528 44.927 49.644 50,006 47.606 43.648 Total Liabilities and equity 9.699 11.593 17.303 21,240 22.497 36.479 49,774 59.284 63.225 63,521 61.034 56,612 Source: Company Gala Morgan &aniey Resoaich EFTA00598628 Morgan Stanley MORGAN STANLEY RESEARCH July 23. 2014 Gilead Sciences Inc. Exhibit 7 Gilead Cash Flow Statement 2009 2010 2011 2012 2013 2014E 2015E 2018E 2017E 2018E 2019E 2020E Nel Income (Loss) 2.626 2.890 2.789 2.574 3.057 13.278 14.919 16.261 14263 12.886 10.722 10.226 Depreciation 8 Arnorlization 213 265 302 278 345 379 423 475 527 581 634 691 Slock.based compensation expense 100 118 152 209 252 318 349 384 423 465 511 583 In-process research antl developmetd impalement charges 136 27 0 0 0 0 0 0 0 0 0 Tax Benefits Related to Employee Stock Options 88 82 37 -2 6 Deterred Income Taxes -42 12 64 -39 -98 0 0 0 0 0 0 0 Anwatoalion of Bond Discount 0 26 27 0 0 0 0 0 Other 64 10 48 -2 105 glfillatli1MHIIMAISAla2HkaM26) Accot.nts receivable. net -356 -349 -376 198 -315 -2.620 -582 -280 469 274 438 48 Inventories -75 -181 -201 -350 -343 -625 -871 -174 198 78 84 .43 Prepaid Expenses -66 20 -14 -129 -170 -1.133 -70 -129 123 25 104 -38 Accowas Payable 204 -4 429 117 -98 362 532 107 -121 -48 -51 26 Arwood Lialalities and taxes payable 275 436 411 318 342 166 11 189 45 -18 -36 10 Deferred Revenue 49 -30 -29 23 22 0 0 0 0 0 0 0 Net cash provided by fined in) operating activities 3.080 2,834 3.639 3.195 3.105 10.168 14.759 16,832 15,927 14,244 12,406 11.483 Purchases Of Marketable Stultifies -2.614 -5.503 -5.128 -1.245 -257 -5.128 -5.128 -5.128 -5.128 2.128 2.128 2.128 Proceeds From Sales Of Marketable Securities 1.441 3.034 8.650 528 494 4.615 4.615 4.615 4.815 4.615 4.615 4.615 Proceeds From t4wwities Of lAarkelable Securities 436 684 788 45 78 2 53 99 140 178 211 241 Acqtisitions. Net &Cash -1.248 -91 -589 -10.752 -379 0 0 0 0 0 0 0 PUICh3305 of PP8E -230 -62 -132 -397 -191 -492 -621 -728 -734 -759 -748 -798 Other -25 0 -218 -21 7 38 21 -3 4 Net cash used in investing activities -2.216 3.590 -11.848 -254 -1.221 -1.102 -1.135 4.071 -1.073 -1.063 -1.066 Cash Flows from Financing Activities Proceeds hoot issuances ol common stock (tor ESO) 223 221 212 466 313 204 184 132 106 85 68 33 Excess tax benefits born SIOCk-based compensation 80 82 41 114 279 162 108 70 51 45 39 20 Proceeds lion, sale otIpayrnents w settle) warrants 155 -1.040 Floceedsr(pmchases) ol converlible note hedges -363 214 2.774 Proceeds foomtirepayrnents ol) debt financing -311 2.457 4.009 305 -4.440 3.759 -750 -1.167 4399 0 0 -499 Contributions from (dstrIbutions to) nonconoolIng Merest -45 132 -115 131 152 Repurchases ol common stock -998 .4.023 -2283 4367 222 -1.320 -4.840 -7.986 -10.542 -11.596 -12.755 Dividends pad 0 -746 2.139 -2.577 2.144 -2.045 Other 0 -3.110 0 0 0 0 0 0 Net cash provided by financing activities -1,051 -1,339 1,784 583 -2,544 -185 -2,643 -7.431 -10,668 -12,989 34 `833_ -16,248 Erect of Exchange Raze Changes on Cash 1 77 -17 8 2 Change in cash -186 -365 8.976 -8.080 309 8.762 11.114 8.266 4.189 182 -2.280 4.229 Cash at berynnow of year 1.459 1.273 908 9.884 1.804 2.113 10.875 21.989 30.255 34.444 34.628 32.346 Lisa al end ci Year 1413 900 9.564 1.504 411.1 10.0/0 L1.Wp 30433 34.444 .54.040 .14..40 2/ toll Sowce. Company Dwa. Morgan Santry Research EFTA00598629 Morgan Stanley MORGAN STANLEY RESEARCH July 23. 2014 Gilead Sciences Inc. 9 EFTA00598630 Morgan Stanley MORGAN STANLEY RESEARCH July 23. 2014 Gilead Sciences Inc. UnP.t.AS ":TANI.C." Morgan Stanley ModelWare is a proprietary analytic framework that helps clients NI ModelWare uncover value, adjusting for distortions and ambiguities created by local accounting regulations. For example. ModelWare EPS adjusts for onetime events, capitalizes operating leases (where their use is significant), and converts inventory from LIFO costing to a FIFO basis. ModelWare also emphasizes the separation of operating performance of a company from its financing for a more complete view of how a company generates earnings. Disclosure Section The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC. and/or Morgan Stanley MIR S.A.. and/or Morgan Stanley Mexico. Casa de Bolsa. S.A. de CV.. ' gan Stanley Canada Limited. M used in this disclosure sec ion, Morgan Stanley includes Morgan Stanley & Co. LLC, Morgan Stanley S.A., Morgan Stanley Mexico, Casa de Bolsa. S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary. For important disclosures, stock price charts and ' ' " " t are the subject of this report, please see the Morgan Stanley Research Disclosure Website at . or contact your investment representative or Morgan Stanley Research at 1585 Broadway, fik en ion: esear anagemen . ew , Y, 10036 USA. For valuation methodology and risks associated with any price targets referent in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303.2495; Hong Kong +852 2848-5989: Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169: Singapore +65 68346860: Sydney +61 (0)2.9770-1505; Tokyo +81 (0)16836.9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway. (Attention: Research Management). New York. NY 10036 USA. Analyst Certification The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Matthew Harrison. Unless otherwise stated. the individuals listed on the cover page of this report are research analysts. Global Research Conflict Management Policy With our conflict management policy. which is available at Important US Regulatory Disclosures on Subject Companies As of June 30, 2014, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Akebia Therapeutics Inc. Alnylam Pharmaceuticals, AMAG Pharmaceuticals. Inc.. Auxilium Pharmaceuticals. Cubist Pharmaceuticals Inc., GW Pharmaceuticals PLC. Idenix Pharmaceuticals. Inc., ImmunoGen Inc.. Ironwood Pharmaceuticals, Inc.. Ophthotech Corp. Within the last 12 months. Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of Akebia Therapeutics Inc. AMAG Pharmaceuticals, Inc., Amgen Inc., Celgene Corp. Chimenx Inc. Cubist Pharmaceuticals Inc., Gilead Sciences Inc.. GW Pharmaceuticals PLC. Ironwood Pharmaceuticals, Inc., Ophthotech Corp. Portola Pharmaceuticals Inc, Relypsa. Inc.. Synageva Biopharma Corp. Ultragenyx Pharmaceutical Inc. Versartis. Inc.. Within the last 12 months. Morgan Stanley has received compensation for investment banking services from Akebia Therapeutics Inc, AMAG Pharmaceuticals. Inc.. Amgen Inc.. Biogen Idec Inc., Celgene Corp. Chimerix Inc, Cubist Pharmaceuticals Inc., Gilead Sciences Inc.. GW Pharmaceuticals PLC. Ironwood Pharmaceuticals. Inc., Ophthotech Corp. Portola Pharmaceuticals Inc, Relypsa. Inc.. Synageva Biopharma Corp. Theravance Inc, Ultragenyx Pharmaceutical Inc, Versartis, Inc.. In the next 3 months. Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Akebia Therapeutics Inc, Alexion Pharmaceuticals. Alnylam Pharmaceuticals, AMAG Pharmaceuticals. Inc., Amgen.Inc., Auxilium Pharmaceuticals, Biogen Idec Inc. Celgene Corp, Chimerix Inc. Cubist Pharmaceuticals Inc.. Gilead Sciences Inc.. GW Pharmaceuticals PLC. ImmunoGen Inc.. Incyte Corporation. Infinity Pharmaceuticals Inc. InterMune. Ironwood Pharmaceuticals, Inc., Lexicon Pharmaceuticals. Inc.. Neurocrine Biosciences Inc. NPS Pharmaceuticals, Ophthotech Corp. Pharmacydics Inc.. Portola Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc., Relypsa, Inc.. Synageva Biopharma Corp, Theravance Inc, Ultragenyx Pharmaceutical Inc, Versartis, Inc., Vertex Pharmaceuticals. XenoPort Inc. Within the last 12 months. Morgan Stanley has received compensation for products and services other than investment banking services from Amgen Inc.. Auxilium Pharmaceuticals. Biogen Mee Inc., Celgene Corp. Cubist Pharmaceuticals Inc., Vertex Pharmaceuticals. Within the last 12 months. Morgan Stanley has provided or is providing investment banking services to. or has an investment banking client relationship with, the following company: Akebia Therapeutics Inc, Alexion Pharmaceuticals. Alnylam Pharmaceuticals. AMAG Pharmaceuticals. Inc., Amgen Inc., Auxilium Pharmaceuticals, Biogen Idec Inc., Celgene Corp, Chimerix Inc. Cubist Pharmaceuticals Inc.. Gilead Sciences Inc.. GW Pharmaceuticals PLC, ImmunoGen Inc., Incyte Corporation, infinity Pharmaceuticals Inc. InterMune, Ironwood Pharmaceuticals. Inc., Lexicon Pharmaceuticals. Inc.. Neurocrine Biosciences Inc, NPS Pharmaceuticals. Ophthotech Corp. Pharmacydics Inc.. Portola Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc.. Relypsa, Inc., Synageva Biopharma Corp, Theravance Inc. Ultragenyx Pharmaceutical Inc, Versartis, Inc., Vertex Pharmaceuticals. XenoPort Inc. Within the last 12 months. Morgan Stanley has either provided or is providing non-investment banking. securities•related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: AMAG Pharmaceuticals. Inc., Amgen Inc.. Auxilium Pharmaceuticals. Biogen Idec Inc., Celgene Corp, Cubist Pharmaceuticals Inc., Gilead Sciences Inc., InterMune, Portola Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc.. Vertex Pharmaceuticals. Morgan Stanley & Co. LLC makes a market in the securities of Akebia Therapeutics Inc, Alexion Pharmaceuticals. Alnylam Pharmaceuticals. AMAG Pharmaceuticals. Inc., Amgen Inc.. Auxilium Pharmaceuticals. Biogen Idec Inc., Celgene Corp, Chimerix Inc, Cubist Pharmaceuticals Inc., Gilead Sciences Inc.. Idenix Pharmaceuticals. Inc.. ImmunoGen Inc.. Incyte Corporation, Infinity Pharmaceuticals Inc, InterMune, Ironwood Pharmaceuticals. Inc.. Lexicon Pharmaceuticals. Inc.. Neurocrine Biosciences Inc, NPS Pharmaceuticals, Ophthotech Corp. Pharmacyclics Inc.. Portola Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc., Relypsa. Inc., Synageva Biopharma Corp. Theravance Inc. Versartis. Inc.. Vertex Pharmaceuticals. XenoPort Inc. The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research. Investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research. including market making. providing liquidity and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Certain disclosures listed above are also for compliance with applicable regulations in non•US jurisdictions. 10 EFTA00598631 Morgan Stanley MORGAN STANLEY RESEARCH July 23. 2014 Gilead Sciences Inc. STOCK RATINGS Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight. Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In adation. since Morgan Stanley Research contains more complete information concerning the analysts views, investors should carefully read Morgan Stanley Research. in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Global Stock Ratings Distribution (as of June 30. 2014) For disclosure purposes only (in accordance with NASD and NYSE requirements). we include the category headings of Buy. Hold. and Sell alongside our ratings of Overweight. Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy. Hold or Sell to the stocks we cover. Overweight, Equal-weight. Not-Rated and Underweight are not the equivalent of buy. hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating. with a buy recommendation: we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively. Coverage Universe Investment Banking Clients (SC) % of Yr of % of Rating Stock Rating Category Count Total Count Total IBC Category Overweight/Buy 1080 35% 367 38% 34% Equal-weight/Hold 1339 44% 469 49% 35% Not-Rated/Hold 113 4% 23 2% 20% Underweight/Sell 546 18% 98 10% 18% Total 3,078 957 Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Analyst Stock Ratings Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis. over the next 12-18 months. Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's Industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months. Not•Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry(or industry teams) coverage universe, on a risk•adjusted basis, over the next 12-18 months. Underweight (U). The stock's total return is expected to be below the average total return of the analyst's Industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months. Unless otherwise specified. the time frame for price targets included in Morgan Stanley Research is 12 to 18 months. Analyst Industry Views Attractive (A): The analyst expects theperformance of his or her industry coverage universe over the next 12.18 months to be attractive vs. the relevant broad market benchmark, as indicated below. In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12.18 months to be in line with the relevant broad market benchmark, as indicated below. Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark. as indicated below. Benchmarks for each region are as follows: North America • 500: Latin America - relevant MSCI country index or MSCI Latin America Index: Europe • MSCI Europe: Japan - TOPIX: Asia - relevant MSC country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index. Stock Price. Price Target and Rating History (See Rating Definitions) 11 EFTA00598632 Morgan Stanley MORGAN STANLEY RESEARCH July 23. 2014 Gilead Sciences Inc. Gilead Sciences Inc. (GILD.0) - As of 7/23/14 in USD Industry : Biotechnology 120 • 0/I 110 FHA 16471 s'1/VI- • Er 100 90 80 ^5 . -.-.- 70 CRIB _tri.r.v.r.„.„,, 60 443 44 SO 40 32.5 ao . res—r-rn 30 20 10 i inistnIJ st ri t:IOINIDIJI Min 4 I II IJ 0 I ISICISINIOI JIrIMISINI . 0701 07.^ : OM 07/01 20 1 201. 20 3 2014 Stock Reline IIlotory i 7/1/11 t WI, 11/21/11 : NA/I) 24/12 1 041 64/13 i NA/17 3/24/14 2 Ea Pr ce Target History: 11/21/11 t NA; 2.4/12 t 32.25) le/4/12 t 31.61 12/14/12 t 43.6) 1443 1 441 2/6/13 t 461 4/22/13 t 66) 6/9/13 1 NA) 3/26/14 t 76) 716114 8 SI Source: Morgan Stanley Research Me Fermat : MINVOIVYY Price Tweet •-• No Price 'forget Assigned (NA) Stock Price (Not Covered byCurrent Analyst) — Stock Price tCesereil by end. Analyse )ma Stock and Industry Ratings (obbrwiation• below) appear • Skids Rotine/Industry View Stock Ratings: Overweight (0) Equal-weight (E) Underweight (U) Not-Rated (IM) No Rating Available (NA) Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR) Effective January 13. 2014. the stocks covered by Mayen Stanley Asia Pacific will be rated relative to the analyst's industry (or industry team's) coverage. Effective January 13. 2014. the industry view benchmarks foe Kwym. Stanley Rsia Pacific we as follow: relevant PISCI country index or MSCI sub-regional index or MSC' AC Asia Pacific ex Jape. Index. Important Disclosures for Morgan Stanley Smith Barney LLC Customers Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or on the Morgan Stanley Wealth Management dsclosure 000 ar For Morgan Stanley specific disclosures. you may refer to Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf ol Morgan Stanley. This could create a conflict of Merest. Other Important Disclosures Morgan Stanley & Co. International PLC and its affiliates have a significant financial interest n the debt securities of Amgen Inc.. Celgene Corp. Cubist Pharmaceuticals Inc.. Gilead Sciences Inc.. Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be. and do no: constitute. advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. Morgan Stanley produces an equity research product called a 'Tactical Idea.' Views contained in a 'Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock This may be the resuff of differing Sipa- hnrinInc m00mr(00000 (000(01 Ttor. or other factors. For all research available on a particular stock. please contact your sales representative or go to Matrix at Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all. Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate 4,0"10100- m0000 m 00000(00000 For access to all available Morgan Stanley Research. please contact your sales representative or go to Matrix at Any access andfor use of Morgan Stanley. Research is subject to Morgan Stanley's Terms of Use -ear using Morgan Stanley Research. you are indicating that you have read and agree to be bound by our erms o se . In ripli um( 000000( M KM(000 q(00100 0(00(000,00 your personal data and usiwg cookies in accordance with our Privacyo cityy an our o 0o ues o icy 1. including for the purposes of setting yow preferences and to coiled readership data so that we can dealer better and more personalized service an p us to you. To find out mor information anent haw AAnraan Stanley 0101,00000 Trsonal data. how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy ( If you do not agree to ow Terms of Use anclicir if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research. Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive n. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investors circumstances and objectives. The securities. instruments. or strategies discussed in Morgan Stanley Research may not be suitable for all investors. and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or set any security/instrument or to participate in any particular tradng strategy. The value of and income from your investments may vary because of changes in interest rates. foren exchange rates. defauff rates. prepayment rates. securiliesinstruments prices. market indexes. operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securitiesinstniments transactions. Past performance is not necessarily a guide to future performance. Estimates 12 EFTA00598633 Morgan Stanley MORGAN STANLEY RESEARCH July 23. 2014 Gilead Sciences Inc. of future performance are based on assumptions that may not be realized. It provided. and unless otherwise slated the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments. The fixed income research analysts. strategists or economists prircipally responsble for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality. accuracy and value of research. Wm profitability or revenues (which include fixed income trading and capital markets profitability or revenues). client feecback and competitive factors. Fixed Income Research analysts, strategists' or economists compensation is not fried to investment banker or capital markets transactions pert ormed by Morgan Stanley or the profitability or revenues of particular trading desks. The Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research. Morgan Stanley may have an investment of less than 1% ei secuntiesinstruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securitiesinstniments or derivatives of securitiesfinstruments of companies mentioned and may trade them in ways afferent from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons. With the exception of information regarcing Morgan Stanley. Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable. comprehensive information, but we make no representation that n is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we .,tend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by. and may not reflect information known to. professionals in other Morgan Stanley business areas. include"; .,vestment banking personnel. Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management. Morgan Stanley may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report. To our readers in Taiwan: Information on securibesanstruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public mesa without the express written consent of Morgan Stanley. Information on securitiesinstniments that do not trade ii Taiwan is for informational purposes only and is nol to be construed as a recommendation or a solicitation to trade in such securitiesinstniments. MSTL may not execute transactions for clients in these securities/instruments. To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf ol. and is attributable to. Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. II you have any queries concerning Morgan Stanley Research. please contact our Hong Kong sales representatives. Morgan Stanley is not incorporated under PRC Law and the research ii relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any stratifies in the PRC. PRC investors shall have the relevant qualifications to invest in such securities :LS.A. and shat be responsible for obtaining al relevant approvals. licenses. verifications and/or registrations from the relevant governmental authorities themselves. Morgan Stanley Research is disseminated in Brazil by Morgan Stanley in Ja T by Morgan Stanley MUFG Securities Co.. Ltd. and. for Commodities related research reports only. Morgan Stanley Capital Grow Japan Co.. :yr one Kong Morgan Stanley Asia Limited (which accepts responsbifity for its contents) and by Bank Morgan Stanley AG. -Hong Kong Branch: II Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 1992062982) anclor Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H). regulated by the Monetary Authority of Singapore (which accepts legal responsbility for its contents and should be contacted with respect to any matters ariskig from, or in connection with. Morgan Stanley Research) and by Bank Morgan Stanley AG. Singapore (Registration number T11FCO207F): in Australia to 'wholesale clients' within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited . 67 003 734 576. holder of Australian Wiancial services license No. 233742. which accepts responsibdily for its contents:'iiit tralia to 'wholesale clients" and a clients' within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Ply Ltd . 19 009 145 555. holder of Australian financial services license No. 2408t3. which accepts responsibility for its contents: in Korea by Morgan Stanley & Co ernational plc. Seoul Branch: in India by Morgan Stanley India Company Private Limited: in Indonesia by PT Morgan Stanley Asia Indonesia: in Canada by Morgan Stanley Canada Limited. which has approved of and takes responsibility for its contents in Canada: in Germany by Morgan Stanley Bank AG. Frankfurt am Main and Morgan Stanley Private Wealth Management Limited. Niededassung Deutschland. regulated by Bundesanstall fuer Finanzebenstlerstungsaufsichl (BaFin): in Spain by Morgan Stanley. S.V.. S.A.. a Morgan Stanley group company. which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to Mandel research as established under Spanish regulations: in the US by Morgan Stanley & Co. LI.C, which accepts responsibilly for its contents. Morgan Stanley & Co. International plc. authorized by the Prudential Regulatory Authority and regulated by the Financial Conduct Authority and the Prudential Regulatory Authority. disserreiales in the UK research that it has prepared. and approves solely for the rposes of section 21 of the Financial Services and Markets Act 2000. research which has been prepared by any of its affiliates. Morgan Stanley Private Wealth Management Limited, authorized and regulated by the Financial Conduct Authority. also iisseminates Morgan Stanley Research in the UK. Private UK investors should obtain the advice of their Morgan Stanley & Co. International plc or Morgan Stanley Private Wealth Management representative about the investments concerned. RMB Morgan Stanley (Proprietary) Limited is a member of the JSE Limited and regulated by the Financial Services Board in South /Oka. RMB Morgan Stanley (Proprietary) Limited is a joint venture owned equally by Morgan Stanley International Holdngs Inc. and RMB Investment Advisory (Proprietary) Limited. which is wholy owned by FirstRand Limited. The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch). regulated by the Dubai Financial Services Authority (the DFSA). and is directed at Professional Clients only. as defined by the DFSA_ The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client. The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (OFC Branch). regulated by the Qatar Errand& Centre Regulatory Authority (the OFCRA). and is directed al business customers and market counterparties only and is not intended for Retail Customers as defined by the OFCRA. As required by the Capital Markets Board of Turkey, investment information. comments and recommendations stated here. are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on thee risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These op.-lions may not fit to your financial status, risk and return preferences. For this reason. to make an investment decision by relying solely to this information slated here may not bring about outcomes that fit your expectations. The trademarks and service marks contained'., Morgan Stanley Research are the property of their respective owners. Thirdparly data providers make no warranties or representations relating to the accuracy. completeness, or timeliness of the data they provide and shall not ti: , - iablity for any damages relating to such data. The Global Industry Classification Standard (GCS) was developed by and is the exclusive property of MSCI and M. Morgan Stanley Research or portions of it may not be reprinted. sold or redstributed without the written consent of Morgan Stanley. Morgan Stanley Research. or any portion thereol may not be reprinted, sold or redistributed without the written consent of Morgan Stanley. 13 EFTA00598634 Morgan Stanley MORGAN STANLEY RESEARCH The Americas Europe Japan Asia/Pacific 1585 Broadway 20 Bank Street. Canary Wharf 1-9-7 Otemachi. Chiyoda-ku 1 Austin Road West New York. NY 10036-8293 London E14 4AD Tokyo 100-8104 Kowloon United States United Kingdom Japan Hong Kong Tel: +1 (1) 212 761 4000 Tel: +44 (0) 20 7 425 8000 Tel: +81 (0) 3 6836 5000 Tel: +852 2848 5200 Pharmacyclics Inc. (PCYC.0) E (03.262014) $103.92 Regeneron Pharmaceuticals Inc. E (01262014) $310.27 (REGN.0) Industry Coverage:Biotechnology Sock Ratings are subject lo change. Phase see !ales: research for each company. ' Ilislohcal prices are rot spit adyslecl. Company (Ticker) Rating (as of)Price• (07/23/2014) David Friedman,M. AMAG Pharmaceuticals. Inc. E(11/212011) $19.04 (AMAG.0) Akebia Therapeutics Inc (AKBA.0) 0 (04/14/2014) $23.19 Alexion Pharmaceuticals (ALXN.0) 0 (09/07/2010) $173.08 Alnylam Pharmaceuticals E (01/14)2014) $55.86 (ALNY.0) Auxilium Pharmaceuticals U (03/06/2014) $19.6 (AUXL.0) Chimerix Inc (CMRX.0) 0 (05/06/2013) $22.87 Cubist Pharmaceuticals Inc. 0(11/132013) $62.58 (CBST.0) GW Pharmaceuticals PLC 0 (04)22/2014) $86.68 (GWPH.0) Idenix Pharmaceuticals. Inc. E(03/182011) $24.32 (IDIX.0) Incyte Corporation (INCY.0) U (01/23/2013) $48.98 InterMune (ITMN.0) E (09/07)2010) $46.4 Ironwood Pharmaceuticals. Inc. E (04)24)2013) $15.05 (IRW0.0) Lexicon Pharmaceuticals. Inc. U(08/11/2013) $1.59 (U(RX.0) NPS Pharmaceuticals (NPSP.0) +• $29.33 Neurosis Biosciences Inc E (01/08/20 4) $13.71 (NBIX.0) Ophthotech Corp (OPHT.0) 0 (10/21/20 3) $40.63 Panda Pharmaceuticals Inc 0 (06/17/20 3) $24.92 (PTLA.0) Relypsa. Inc. (RLYP.0) 0 (12/10/20 3) $24.98 Synageva Biopharma Corp 0 (04)20/20 2) $72.44 (GEVk0) Theravance Inc (THRX.0) U (07/22/20 3) $25.32 Ultragenyx Pharmaceutical Inc 0 (02/25/20 4) $43.05 (RARE.0) Versartis. Inc. (VSAR.0) 0 (04/15/20 4) $23.45 Vertex Pharmaceuticals (VRTX.0) E (05/08/20 2) $98.14 XenoPorl Inc (XNPT.0) U (06/11/20 3) $4.39 Matthew Harrison Amgen Inc. (AMGN.0) 0 (03/2620 4) $122.01 Bingen Idec Inc. (BIIB.0) 0 (03'26/20 4) $337.6 Celgene Corp (CELG.0) E (0326/20 4) $89.12 Gaead Sciences Inc. (GILD.0) E (03/26/20 4) $90.34 ImmunoGen Inc. (IMGN.0) U (06/25/20 4) $11.38 Infinity Pharmaceuticals Inc 0 (06/25/20 4) $9.82 (INFLO) 0 2014 Morgan Stanley EFTA00598635